Receptor Logic Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Receptor Logic Ltd.
Receptor Logic has a means of making antibodies that mimic the scouting and identifying functions of T-cells by binding to peptides that appear on the surface of cells, within the frame of the major histocompatability complex. The start-up thinks its antibodies will accelerate research on T-cell-stimulating vaccines (versus prophylactic ones) and will ultimately serve as therapeutics in their own right.
New approaches to cancer immunotherapy promise to change the face of cancer care in a way that will reverberate through the field for years to come. In this issue, we profile Borean Pharma, OncoMed Pharmaceuticals and Receptor Logic.
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Next-Generation Cancer Immunotherapies, features profiles of Borean Pharma, OncoMed Pharmaceuticals, ProNAi Therapeutics and Receptor Logic. Plus these Start-Ups across Health Care: CeraPedics, DiObex and Endothelix.
In Vivo briefly summarizes the technologies of these recently founded companies: AGI Therapeutics Ltd., Angiosyn Inc., etexx Biopharmaceuticals Inc., Nuvios Inc., Orthonics Inc. and Receptor Logic Ltd.
- Drug Discovery Tools